Bausch + Lomb’s Vyzulta has been issued a Notice of Compliance from Health Canada for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release.
Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), a once-daily monotherapy that targets two pathways to reduce aqueous humor to lower IOP, is the first new open-angle glaucoma treatment in Canada in nearly two decades, the release said.
“With today’s approval of Vyzulta, doctors and patients with glaucoma now have a new innovative treatment option that can help provide
Uncategorized